Keyphrases
Schisandrin B
100%
ATG16L1
100%
Parkinson's Disease
100%
NLRP3 Pathway
100%
Alpha-synuclein (α-syn)
100%
NLRP3 Inflammasome
66%
Autophagy
66%
Molecular Mechanism
33%
Preformed Fibrils
33%
PD Model
33%
Stereotaxic Injection
33%
Neuroinflammation
16%
Protective Effect
16%
Motor Behavior
16%
Cell Biology
16%
Molecular Biology Experiments
16%
Pharmacological Effects
16%
Adenovirus
16%
Autophagy Dysfunction
16%
Preclinical Efficacy
16%
Substantia Nigra
16%
Microglia
16%
Neurotoxicity
16%
Expected Outcomes
16%
Orally Administered
16%
Behavioral Tests
16%
Lipopolysaccharide
16%
Neuroprotective Effect
16%
C57BL
16%
Induced Models
16%
Medicine and Dentistry
Signal Transduction
100%
Synuclein
100%
NLR Family Pyrin Domain containing 3
100%
Treatment of Parkinson's Disease
100%
Schizandrin B
100%
Autophagy
83%
NLRP3 Inflammasome
66%
Fibril
33%
Microglia
16%
Neuroinflammation
16%
C57BL/6
16%
In Vitro
16%
Lipopolysaccharide
16%
Adeno-Associated Virus
16%
Locomotion
16%
Neuroprotective Agent
16%
Neurotoxicity
16%
Substantia nigra
16%
Neuroscience
Treatment of Parkinson's Disease
100%
Schizandrin B
100%
Synuclein
100%
Autophagy
83%
Inflammasome
66%
In Vivo
33%
Substantia nigra
16%
In Vitro
16%
Behavior (Neuroscience)
16%
Neuroprotective Agent
16%
Microglia
16%
Lipopolysaccharide
16%
Adeno-Associated Virus
16%
Neurotoxicity
16%